Insight Molecular Diagnostics Inc. — Director's Dealing 2018

Jun 4, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2018-05-23

Reporting Person: HESTERBERG LYNDAL K. (Sr VP, Research & Development)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-23	Option to Purchase Common Stock	$2.35	A	150000	Acquired	2028-05-22	Common Stock (150000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$4.70	2027-02-16	Common Stock (14400)	14400	Direct
Option to Purchase Common Stock	$4.05	2026-10-31	Common Stock (125000)	125000	Direct
Option to Purchase Common Stock	$3.06	2026-02-15	Common Stock (25000)	25000	Direct

Footnotes

F1: These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.

F2: One quarter of the options vested on October 31, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.

F3: One quarter of the options vested on February 15, 2017 and one quarter vested on February 15, 2018, and the balance shall vest upon the attainment of certain product development milestones, in each case depending upon continuous employment by the Company.